Newly formed independent business, Sterilin Ltd., is aiming to increase the quality of laboratory analyses with its range of single-use labware.
Ensuring that sample analyses are accurate not only involves ensuring analysis protocols are suitable, but also that the samples analysed are not contaminated in any way. This becomes particularly important in medical laboratories, where any contaminants could adversely affect analysis results and subsequent diagnosis.
According to Sterlin's CEO, John Adkins, the key benefits of using single use laboratory plastics are assured sterility, convenience and reliability. This helps scientists be more confident in their analyses as well as helping to increase efficiency as there is no need for washing or sterilising the labware.
The firm was born after the sale of Barloworld's Scientific Laboratory Group to Nova Capital for £74m (€107.3m) at the end of last year. At the time of the sale, Barloworld's CEO, Clive Thompson explained that Barloworld had decided to "reposition as a focussed distribution company and unlock shareholder value."
Nova Capital subsequently reorganised the group into four separate entities, Bibby Scientific, SciLabware, Carbolite and Sterilin.
The Sterilin product range was established over 40 years ago to address the needs of the microbiologists working in the clinical sector, and has a product range of over 1000 items including both the Sterilin single use plastic range and the Iwaki tissue culture range. Its 30ml leak free universal container, 90mm triple vent Petri dish and 10ml pipettes are some of the company's leading product lines.
In recent years the Sterilin range has evolved with user needs to address much wider market sectors including food, industrial, pharmaceutical and forensics. According to Adkins, the firm is also exploring new opportunities in advancing areas of science including those offered by the increasing use of automation.
"The new company structure enables the management team to be more focussed and will enable the Sterilin team to better understand customer requirements and technology developments within the life science market sector," said Adkins.
"This will enable us to become a more innovative organization and develop a stream of new products to address changing customer needs. We currently have several new products under development that address specific issues within the clinical sector."
He continued by saying that as a new and separate entity, Sterilin has had to establish many independent functions including the distribution of products to customers. To ensure the transition runs seamlessly, the current customer service team remains unchanged so that the same experienced people are dealing with customer accounts, orders and queries.
The firm will continue to use its ISO 9001:2000 accredited manufacturing facility in South Wales, where "a commitment to continuous product development and investment ensures that every item is made to the highest possible quality."